Rivanicline-d3

Rivanicline-d3 (RJR-2403-d3) is the deuterium labeled Rivanicline. Rivanicline (RJR-2403) is a neuronal nicotinic receptor agonist.[1][2][3][4][5].

220088-40-4

RJR-2403-d3; (E) -Metanicotine-d3

12352005

Isotope-Labeled Compounds

Others

Neuroscience-Neuromodulation

Neurological Disease

[2H]C([2H])(NCC/C=C/C1=CC=CN=C1)[2H]

C10H11D3N2

165.25

[1]Bencherif M, et al. RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. J Pharmacol Exp Ther. 1996 Dec;279 (3) :1413-21.|[2]Lippiello PM, et al. RJR-2403: a nicotinic agonist with CNS selectivity II. In vivo characterization. J Pharmacol Exp Ther. 1996 Dec;279 (3) :1422-9.|[3]Damaj MI, et al. Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist. J Pharmacol Exp Ther. 1999 Oct;291 (1) :390-8.|[4]Papke RL, et al The activation and inhibition of human nicotinic acetylcholine receptor by RJR-2403 indicate a selectivity for the alpha4beta2 receptor subtype. J Neurochem. 2000 Jul;75 (1) :204-16. |[5]Rodríguez-Moreno A, et al. The nicotinic agonist RJR-2403 compensates the impairment of eyeblink conditioning produced by the noncompetitive NMDA-receptor antagonist MK-801. Neurosci Lett. 2006 Jul 10;402 (1-2) :102-7.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W745872/

Isotope-Labeled Compounds

No Development Reported